Holen Sie sich die Stockscreener-App
40.13
1.31%
0.52
Handel nachbörslich:
40.13
Schlusskurs vom Vortag:
$39.61
Offen:
$40.548
24-Stunden-Volumen:
584.71K
Relative Volume:
1.30
Marktkapitalisierung:
$719.83M
Einnahmen:
$116.88M
Nettoeinkommen (Verlust:
$-25.09M
KGV:
-286.64
EPS:
-0.14
Netto-Cashflow:
$-20.74M
1W Leistung:
+2.09%
1M Leistung:
+77.02%
6M Leistung:
+81.75%
1J Leistung:
+204.48%
1-Tages-Spanne:
$38.18
$40.55
1-Wochen-Bereich:
$37.81
$40.55
52-Wochen-Spanne:
$12.66
$43.72
Rigel Pharmaceuticals Stock (RIGL) Company Profile
Firmenname
Rigel Pharmaceuticals
Sektor
Branche
Telefon
650-624-1100
Adresse
611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA
Vergleichen Sie RIGL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RIGL
Rigel Pharmaceuticals
|
40.13 | 689.87M | 116.88M | -25.09M | -20.74M | -0.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Rigel Pharmaceuticals Stock (RIGL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-04-03 | Fortgesetzt | Piper Sandler | Neutral |
| 2022-06-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-06-08 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2022-06-08 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-03-23 | Eingeleitet | B. Riley Securities | Neutral |
| 2020-11-09 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-11-15 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2019-09-26 | Fortgesetzt | JP Morgan | Overweight |
| 2019-03-01 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2018-08-27 | Eingeleitet | Citigroup | Buy |
| 2018-05-02 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2017-12-21 | Fortgesetzt | Piper Jaffray | Overweight |
| 2017-12-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-11-06 | Fortgesetzt | H.C. Wainwright | Buy |
| 2017-03-09 | Bestätigt | H.C. Wainwright | Buy |
| 2016-08-31 | Bestätigt | H.C. Wainwright | Buy |
| 2016-08-30 | Bestätigt | Piper Jaffray | Overweight |
| 2016-07-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-06-13 | Eingeleitet | Piper Jaffray | Overweight |
| 2016-04-22 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2013-04-08 | Bestätigt | Stifel | Buy |
| 2012-11-29 | Eingeleitet | UBS | Neutral |
| 2012-11-06 | Bestätigt | Oppenheimer | Outperform |
| 2012-03-26 | Eingeleitet | Canaccord Genuity | Hold |
| 2010-12-10 | Herabstufung | MP Advisors | Outperform → Market Perform |
Alle ansehen
Rigel Pharmaceuticals Aktie (RIGL) Neueste Nachrichten
Rigel Pharmaceuticals Inc. stock prediction for this weekMarket Trend Summary & Risk Managed Investment Signals - Newser
Analyzing recovery setups for Rigel Pharmaceuticals Inc. investorsEarnings Risk Report & AI Enhanced Trading Alerts - Newser
What are Rigel Pharmaceuticals Inc.’s recent SEC filings showingEarnings Trend Report & Weekly Stock Performance Updates - khodrobank.com
Is Rigel Pharmaceuticals Inc.’s growth already priced inTrade Entry Report & Expert-Curated Trade Recommendations - khodrobank.com
Historical volatility pattern of Rigel Pharmaceuticals Inc. visualizedGap Up & Weekly Setup with High ROI Potential - Newser
Tools to monitor Rigel Pharmaceuticals Inc. recovery probabilityWeekly Investment Recap & Free Growth Oriented Trading Recommendations - Newser
Can technical indicators confirm Rigel Pharmaceuticals Inc.’s reversalWatch List & Safe Entry Point Identification - Newser
Sector ETF performance correlation with Rigel Pharmaceuticals Inc.July 2025 Institutional & Fast Entry and Exit Trade Plans - Newser
Will Rigel Pharmaceuticals Inc. bounce back from current supportJuly 2025 Reactions & Free Reliable Trade Execution Plans - Newser
Is Rigel Pharmaceuticals Inc. a candidate for recovery playOil Prices & Real-Time Stock Entry Alerts - Newser
Will a bounce in Rigel Pharmaceuticals Inc. offer an exitQuarterly Investment Review & AI Forecasted Stock Moves - Newser
Can Rigel Pharmaceuticals Inc. lead its sector in growthWeekly Trade Report & Real-Time Chart Pattern Alerts - khodrobank.com
Rigel Pharmaceuticals at Cantor Conference: Strategic Growth and Expansion - Investing.com
Will Rigel Pharmaceuticals Inc. continue its uptrendSwing Trade & Expert Verified Stock Movement Alerts - Newser
Using R and stats models for Rigel Pharmaceuticals Inc. forecastingTake Profit & Growth Oriented Trade Recommendations - Newser
Does Rigel Pharmaceuticals (NASDAQ:RIGL) Have A Healthy Balance Sheet? - simplywall.st
Smart tools for monitoring Rigel Pharmaceuticals Inc.’s price actionJuly 2025 Action & Fast Entry and Exit Trade Plans - Newser
What earnings revisions data tells us about Rigel Pharmaceuticals Inc.2025 Market Overview & Fast Moving Trade Plans - Newser
Rigel Pharmaceuticals Inc. stock outlook for YEARWeekly Profit Recap & Verified Trade Idea Suggestions - Newser
Multi asset correlation models including Rigel Pharmaceuticals Inc.Trend Reversal & Reliable Entry Point Trade Alerts - Newser
Can Rigel Pharmaceuticals Inc. continue delivering strong returns - khodrobank.com
What is Rigel Pharmaceuticals Inc. s debt to equity ratioWeekly Stock Recap & Community Shared Stock Ideas - khodrobank.com
Can Rigel Pharmaceuticals Inc. navigate macro headwindsQuarterly Portfolio Report & Verified Entry Point Signals - khodrobank.com
Backtesting results for Rigel Pharmaceuticals Inc. trading strategiesTrade Volume Report & Long-Term Safe Investment Ideas - Newser
Price momentum metrics for Rigel Pharmaceuticals Inc. explained2025 Market Sentiment & Weekly Watchlist for Hot Stocks - Newser
Will Rigel Pharmaceuticals Inc. Reverse From Oversold ConditionsJuly 2025 Institutional & Capital Protection Trading Alerts - beatles.ru
Rigel Pharmaceuticals shares fall 1.13% premarket after DelveInsight's report on TGFB Inhibitor pipeline. - AInvest
Why is Rigel Pharmaceuticals Inc. stock going downMarket Sentiment Review & Precise Trade Entry Recommendations - khodrobank.com
Evaluating Rigel Pharmaceuticals Inc. with trendline analysisJuly 2025 Weekly Recap & Technical Buy Zone Confirmations - Newser
Is Rigel Pharmaceuticals Inc. part of any major index2025 Retail Activity & Weekly Top Gainers Trade List - khodrobank.com
Can swing trading help recover from Rigel Pharmaceuticals Inc. lossesPortfolio Risk Summary & Low Drawdown Momentum Trade Ideas - Newser
Technical analysis overview for Rigel Pharmaceuticals Inc. stockWeekly Risk Report & Free Real-Time Volume Trigger Notifications - Newser
Visualizing Rigel Pharmaceuticals Inc. stock with heatmapsJuly 2025 PostEarnings & Verified Trade Idea Suggestions - Newser
Price action breakdown for Rigel Pharmaceuticals Inc.GDP Growth & AI Forecast Swing Trade Picks - Newser
What Fibonacci levels say about Rigel Pharmaceuticals Inc. reboundWeekly Loss Report & Reliable Intraday Trade Plans - Newser
Published on: 2025-08-31 22:19:31 - beatles.ru
Pattern recognition hints at Rigel Pharmaceuticals Inc. upsideQuarterly Risk Review & Weekly Return Optimization Alerts - Newser
Technical signs of recovery in Rigel Pharmaceuticals Inc.2025 Fundamental Recap & Fast Gain Swing Trade Alerts - Newser
Rigel Pharmaceuticals Inc. Stock Flags Risk Zone in Volatility Index getLinesFromResByArray error: size == 0 - classian.co.kr
Tick level data insight on Rigel Pharmaceuticals Inc. volatility2025 Price Targets & Scalable Portfolio Growth Ideas - Newser
Finanzdaten der Rigel Pharmaceuticals-Aktie (RIGL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Rigel Pharmaceuticals-Aktie (RIGL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Schorno Dean L | EVP & Chief Financial Officer |
Feb 05 '25 |
Sale |
21.93 |
1,734 |
38,020 |
57,235 |
| Santos David A | EVP, Chief Commercial Officer |
Feb 04 '25 |
Sale |
20.92 |
2,125 |
44,457 |
53,500 |
| Santos David A | EVP, Chief Commercial Officer |
Feb 05 '25 |
Sale |
21.93 |
1,796 |
39,379 |
51,704 |
| RODRIGUEZ RAUL R | CEO, President |
Feb 04 '25 |
Sale |
20.92 |
4,952 |
103,601 |
243,854 |
| RODRIGUEZ RAUL R | CEO, President |
Feb 05 '25 |
Sale |
21.93 |
4,400 |
96,474 |
239,454 |
| Furey Raymond J. | EVP, GC, CCO & Corp Sec |
Feb 04 '25 |
Sale |
20.92 |
1,448 |
30,294 |
40,169 |
| Furey Raymond J. | EVP, GC, CCO & Corp Sec |
Feb 05 '25 |
Sale |
21.93 |
1,339 |
29,359 |
38,830 |
1.75%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):